Market accessCompany release

Veracyte third-quarter revenue rises 15% to $151.8M; $100M buyback approved, guidance narrowed

🇺🇸 Veracyte, Inc. (VCYT) · Wed 04 Nov 2026

The cancer diagnostics company also bought Convergent Genomics, won Medicare coverage for Prosigna and lowered its full-year testing revenue forecast.

Veracyte reported third-quarter 2026 results on 4 November, with revenue up 15% to $151.8 million. The company attributed the growth to its Decipher Prostate and Afirma testing, and it posted net income of $31.5 million.

The company also acquired Convergent Genomics, adding a urine-based test for bladder cancer. The source summary does not give financial terms or a timeline for launching the technology.

On the reimbursement side, Veracyte secured Medicare coverage for Prosigna, its breast cancer recurrence test. No details of the coverage scope or effective date are available in the material provided.

Veracyte's board authorised a share repurchase of up to $100 million over 12 months. Full-year 2026 revenue guidance was narrowed to $590 million to $593 million, and the forecast for testing revenue was lowered.

What it means for your team

  • Medicare coverage for Prosigna is a market-access milestone for a breast cancer recurrence test; teams should check the coverage policy for scope and criteria once it is published.
  • The Convergent Genomics acquisition signals Veracyte's move into urine-based bladder cancer testing, a segment to watch for future evidence and reimbursement filings.
  • The lower testing revenue forecast, despite 15% quarterly growth, suggests payers, volumes or mix may temper expectations for diagnostics uptake; the reasons are not given in the available material.

Company's press release (SEC filing): Veracyte, Inc. ↗

Article written by VigiEye from the official source (Veracyte, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Market access All →